WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)--Abacus Health Products, Inc. (CSE:ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that it will participate in the 2nd Annual Boston Cannabis Conference presented by Cowen. The event will be held November 11th – 13th 2019 at The Intercontinental Hotel in Boston, MA.
Abacus’ CEO Perry Antelman will participate in a panel discussion on CBD alongside other leading CBD companies. Abacus has also confirmed Cowen CEO Jeffrey Solomon will sit down with Rob Gronkowski for a fireside chat that will highlight Abacus’ recent partnership with the three-time football world champion. Abacus will be available for 1-on-1 meetings throughout the conference.
About Abacus Health Products, Inc.
Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: CBD CLINIC™, marketed to the professional practitioner market, and CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.
To learn more about Abacus, visit www.abacushp.com